Merck & Co., Inc. (NYSE:MRK) Shares Bought by Rhumbline Advisers

Rhumbline Advisers lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 1.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,716,890 shares of the company’s stock after purchasing an additional 35,622 shares during the quarter. Rhumbline Advisers owned about 0.15% of Merck & Co., Inc. worth $284,862,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Financial Avengers Inc. increased its stake in shares of Merck & Co., Inc. by 115.8% during the fourth quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock worth $25,000 after buying an additional 176 shares during the period. Moisand Fitzgerald Tamayo LLC increased its stake in Merck & Co., Inc. by 78.0% in the fourth quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock valued at $27,000 after purchasing an additional 156 shares during the last quarter. Retirement Group LLC increased its stake in Merck & Co., Inc. by 116.4% in the third quarter. Retirement Group LLC now owns 608 shares of the company’s stock valued at $30,000 after purchasing an additional 327 shares during the last quarter. Bellwether Advisors LLC increased its stake in Merck & Co., Inc. by 460.0% in the third quarter. Bellwether Advisors LLC now owns 420 shares of the company’s stock valued at $31,000 after purchasing an additional 345 shares during the last quarter. Finally, Steward Financial Group LLC purchased a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $40,000. 72.88% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently issued reports on MRK shares. SVB Leerink lowered their target price on shares of Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. Morgan Stanley decreased their price target on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. Barclays raised their target price on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a report on Tuesday, April 12th. JPMorgan Chase & Co. reduced their target price on Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating for the company in a report on Friday, January 28th. Finally, StockNews.com initiated coverage on Merck & Co., Inc. in a report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $90.69.

Shares of NYSE MRK traded down $0.42 during trading on Friday, reaching $90.41. The stock had a trading volume of 10,308,067 shares, compared to its average volume of 11,242,952. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $91.40. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.02 and a current ratio of 1.27. The stock has a market cap of $228.63 billion, a PE ratio of 16.17, a P/E/G ratio of 1.20 and a beta of 0.37. The firm’s 50 day moving average price is $83.97 and its two-hundred day moving average price is $80.70.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its quarterly earnings results on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.31. Merck & Co., Inc. had a return on equity of 49.57% and a net margin of 26.27%. The company had revenue of $15.90 billion during the quarter, compared to analysts’ expectations of $14.64 billion. During the same quarter in the prior year, the business posted $1.40 earnings per share. The company’s revenue for the quarter was up 31.6% compared to the same quarter last year. On average, research analysts expect that Merck & Co., Inc. will post 7.31 earnings per share for the current year.

About Merck & Co., Inc. (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.